Press Releases

Date Title and Summary
Toggle Summary Erasmus MC Completes First Step in the Evolution of Online Adaptive Radiation Therapy with the CyberKnife® System
New Clinical Trial Evaluates Use of Online-Adaptive Stereotactic Body Radiation Therapy Approach in the Treatment of Oligometastases SUNNYVALE, Calif. and ROTTERDAM, Netherlands, March 27, 2018 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) and Erasmus MC, the largest university medical
Toggle Summary Accuray to Present at the 2018 RBC Capital Markets Global Healthcare Conference on February 22, 2018
SUNNYVALE, Calif. , Feb. 15, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will present at the 2018 RBC Capital Markets Global Healthcare Conference at the Lotte New York Palace Hotel in New York on Thursday, February 22, 2018 .
Toggle Summary Accuray Retires February 2018 Convertible Notes
-- Company Continues to Execute Strategies to Reduce Total Debt While Minimizing Shareholder Dilution -- SUNNYVALE, Calif. , Feb. 5, 2018 /PRNewswire/ --  Accuray Incorporated  (NASDAQ: ARAY) announced today it has retired all February 2018 convertible notes, including $13 million aggregate
Toggle Summary Study Shows CyberKnife® System Provides Long-Lasting Pain Relief for Trigeminal Neuralgia Patients
CyberKnife Frameless Radiosurgery Offers a Precise and Non-Invasive Technique with Clinical Outcomes Similar to Gamma Knife Frame-Based Invasive Radiosurgery SUNNYVALE, Calif. , Jan. 29, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from a study of 138 patients
Toggle Summary Accuray Fiscal Second Quarter Revenue Exceeds $100 Million and Increases 15 Percent Year-over-Year; Gross Orders of $77.9 Million; Backlog Up 10 Percent
SUNNYVALE, Calif. , Jan. 23, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second fiscal quarter ended December 31, 2017 . Fiscal Second Quarter Highlights Revenue increased 15 percent year-over-year to $100.3 million driven by product revenue
Toggle Summary Beverly A. Huss Joins Accuray Board of Directors
SUNNYVALE, Calif. , Jan. 11, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Beverly A. Huss to the company's Board of Directors, effective January 7, 2018 . Ms. Huss also currently serves on the boards of Qool Therapeutics, Inc. , Surefire Medical, Inc.
Toggle Summary Accuray To Report Fiscal 2018 Second Quarter Financial Results On January 23, 2018
SUNNYVALE, Calif. , Jan. 10, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its second quarter ended December 31, 2017 on Tuesday, January 23, 2018 after the market close. Management will host a conference call to review the results at 1:30 p.m. PT / 4:30 p.m.
Toggle Summary Accuray Elects Net Share Settlement for 3.50% Series A Convertible Senior Notes Due 2018
Company will pay principal in cash and deliver shares for any excess conversion value SUNNYVALE, Calif. , Jan. 3, 2018 /PRNewswire/ --  Accuray Incorporated  (NASDAQ: ARAY) has made an irrevocable Net Share Settlement Election with respect to its 3.50% Series A Convertible Senior Notes due February
Toggle Summary Accuray to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 10, 2018
SUNNYVALE, Calif. , Jan. 3, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Company will present at the J.P. Morgan 36th Annual Healthcare Conference on Wednesday, January 10, 2018 at the Westin St. Francis Hotel in San Francisco .
Toggle Summary Accuray Enters into $40 Million Term Loan; Company Intends to Retire Principal Amount of February 2018 Convertible Notes with Cash at Maturity
Company Also Modifies Revolving Loan Agreement SUNNYVALE, Calif. , Dec. 21, 2017 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today it closed a new $40 million term loan with MidCap Financial Trust while concurrently reducing the borrowing facility under its existing revolving